Medical Patent News

RSS

US District Court upholds validity and enforceability of CRESTOR patent

AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

30 Jun 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology and product line.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

International Stem Cell congratulates ACT on the issuance of its recent patent

International Stem Cell Corporation, www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, congratulates Advanced Cell Technology, Inc. on the issuance of its recent patent, U.S. Patent Number 7,736,896, covering a method for producing retinal pigment epithelial cells.

24 Jun 2010

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.

24 Jun 2010

USPTO rules against claims in LifeWatch '878 patent

Medicomp, Inc. confirmed that it has received an initial ruling by the United States Patent and Trademark Office (USPTO) to reject all claims in regards to LifeWatch patent 7,542,878 (the '878 patent).

24 Jun 2010

UK court finds Smith & Nephew's Renasys EZ and Go products infringe KCI patents

Kinetic Concepts, Inc. today announced that the High Court of Justice Chancery Division, Patents Court in the United Kingdom has found that Smith & Nephew plc's Renasys EZ and Go products infringe two KCI patents relating to negative pressure wound therapy.

24 Jun 2010

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Aphios Corporation today announced that it was awarded United States Patent No. 7,708,915 B2 for "Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein," granted May 04, 2010. This invention is an improved process to formulate polymeric microspheres and nanospheres, and encapsulate therapeutic proteins or other useful substances, and a polymer microspheres/nanospheres apparatus.

24 Jun 2010

K-State chemical engineer patents chemical structure to make natural personal care products in lab

A Kansas State University chemical engineer has developed and patented a chemical structure to make all-natural personal care products and purer pharmaceuticals in the laboratory.

23 Jun 2010

Corgenix receives new European patent for AtherOx technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

23 Jun 2010

USPTO issues patent related to Derma Sciences' MEDIHONEY Calcium Alginate Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.

22 Jun 2010

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Sun Pharmaceutical Industries Ltd. announced that together with its affiliates ("Sun Pharma") it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the United States against Sun Pharma regarding submission of Abbreviated New Drug Applications (ANDAs) for generic versions of Stalevo® and Comtan® tablets.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

19 Jun 2010

Precision announces USPTO's issuance of Actions Closing Prosecution in reexamination proceedings for '545, '605 patents

Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has now issued Actions Closing Prosecution in the reexamination proceedings for both U.S. Pat. No. 6,610,545 ("the '545 patent") and U.S. Pat. No. 7,309,605 ("the '605 patent") that are owned by the Institut Pasteur and the Universite Pierre et Marie Curie (UPMC), and licensed to Cellectis, SA (ALCLS).

18 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "John et al." patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length.

18 Jun 2010

Medical Patent News

US District Court upholds validity and enforceability of CRESTOR patent

USPTO grants Vermillion Alzheimer's disease biomarker patent

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

International Stem Cell congratulates ACT on the issuance of its recent patent

USPTO confirms validity of DUSA's key Levulan PDT patent

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

USPTO rules against claims in LifeWatch '878 patent

UK court finds Smith & Nephew's Renasys EZ and Go products infringe KCI patents

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

K-State chemical engineer patents chemical structure to make natural personal care products in lab

Corgenix receives new European patent for AtherOx technology

USPTO issues patent related to Derma Sciences' MEDIHONEY Calcium Alginate Dressing

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Biodesix awarded US patent for VeriStrat serum test

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Precision announces USPTO's issuance of Actions Closing Prosecution in reexamination proceedings for '545, '605 patents

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News